| Dr Julio Armando Sepulveda Franco, | |
|
101 Calle Comercio, Juana Diaz, PR 00795-1647 | |
| (787) 260-2334 | |
| (787) 260-1846 |
| Full Name | Dr Julio Armando Sepulveda Franco |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 101 Calle Comercio, Juana Diaz, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811983422 | NPI | - | NPPES |
| 74204 J DIAZ | Other | ATLANTIC CARE MEDICAL SER | |
| 38505 (5012) | Other | ASOCIACION DE MAESTROS | |
| 7310151 | Other | HUMANA | |
| 0083749 | Other | PONCE | |
| 1111051 | Other | ACCA | |
| 065615 (M5615) | Other | CRUZ AZUL | |
| 7310151 | Other | HUMANA INSURANCE | |
| 83749 | Other | MEDICARE OPTIMO | |
| 7310151 | Other | HUMANA HEALTH PLAN | |
| 74209 PONCE | Other | ATLANTIC CARE MEDICAL SER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 10183 (Puerto Rico) | Primary |
| Entity Name | Asociacion Cardiovascular Del Sur De Puerto Rico Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851361760 PECOS PAC ID: 8527344365 Enrollment ID: O20170411001166 |
News Archive
Contrary to the common perception among physicians that poor people sue doctors more frequently, Ramon L. Jimenez from the Monterey Orthopaedic and Sports Medicine Institute and his team demonstrate that socioeconomically disadvantaged patients, in fact, tend to sue physicians less often.
Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
An ambitious new study of genes in Asian populations is filling in big gaps in our understanding of human genetics, shedding light on the history of human migration and ultimately aiming to improve our ability to treat disease.
The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julio Armando Sepulveda Franco, Po Box 7335, Ponce, PR 00732-7335 Ph: (787) 260-2334 | Dr Julio Armando Sepulveda Franco, 101 Calle Comercio, Juana Diaz, PR 00795-1647 Ph: (787) 260-2334 |
News Archive
Contrary to the common perception among physicians that poor people sue doctors more frequently, Ramon L. Jimenez from the Monterey Orthopaedic and Sports Medicine Institute and his team demonstrate that socioeconomically disadvantaged patients, in fact, tend to sue physicians less often.
Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
An ambitious new study of genes in Asian populations is filling in big gaps in our understanding of human genetics, shedding light on the history of human migration and ultimately aiming to improve our ability to treat disease.
The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.
› Verified 1 days ago
Dr. Norma Vergne - Santiago, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 100 Calle Comercio Ste 5, Juana Diaz, PR 00795 Phone: 787-260-0480 Fax: 787-260-0480 | |
Mr. Ariel F Morciglio Sr., MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6 Calle Angel R Mora, Juana Diaz, PR 00795 Phone: 787-260-4887 Fax: 787-260-4887 | |
Dr. Andres Alberto Aviles, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 66 Calle Munoz Rivera, Juana Diaz, PR 00795 Phone: 787-260-7849 | |
Dr. Robert A Engel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 43 Degetau Street, Juana Diaz, PR 00795 Phone: 787-260-8254 Fax: 787-260-8254 | |
Carlos M Claudio-rodriguez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Parque Industrial Amuelas, Suite 105 Carratera 584 #531, Juana Diaz, PR 00795 Phone: 787-260-6670 Fax: 787-260-6976 | |
Dr. Daniel Alfonso Ruiz-soler, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Street Num 149 Km 63.8, Edificio Cruz Suite 4 Bo Guayabal, Juana Diaz, PR 00795 Phone: 787-837-5577 Fax: 787-837-5577 |